David Mauro
MD, PhD
Chief Medical Officer
👥Biography 个人简介
David Mauro leads clinical development of novel CDK12 and CDK13 inhibitors for cancers harboring DNA damage repair defects. His work translates synthetic lethal targeting of CDK12 altered tumors into early phase trials across prostate and ovarian cancers. He has a strong background in molecular oncology and translational development of precision therapies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 David Mauro 的研究动态
Follow David Mauro's research updates
留下邮箱，当我们发布与 David Mauro（Aurigene Oncology）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment